Dr. Kai He, MD, PhD
Claim this profileThe Ohio State University James Cancer Center
Area of expertise
Lung Cancer
Kai He, MD, PhD has run 3 trials for Lung Cancer. Some of their research focus areas include:
Solid Tumors
Kai He, MD, PhD has run 3 trials for Solid Tumors. Some of their research focus areas include:
Affiliated Hospitals
The Ohio State University James Cancer Center
The Ohio State University Wexner Medical Center - Thoracic Oncology Clinic
Clinical Trials Kai He, MD, PhD is currently running
ONC-392 vs Chemotherapy
for Lung Cancer
This trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
Recruiting
2 awards
Phase 3
10 criteria
AI-081 Antibody
for Advanced Cancer
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
Recruiting
1 award
Phase 1 & 2
5 criteria
More about Kai He, MD, PhD
Clinical Trial Related
7 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Kai He, MD, PhD has experience with
- Pembrolizumab
- ONC-392
- Docetaxel
- Lete-cel
- TAK-981
- Sitravatinib
Breakdown of trials Kai He, MD, PhD has run
Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Gotistobart vs Chemotherapy for Lung Cancer
- ONC-392 + Pembrolizumab for Non-Small Cell Lung Cancer
Solid Tumors
Non-Small Cell Lung Cancer
Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- ONC-392 + Pembrolizumab for Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kai He, MD, PhD specialize in?
Kai He, MD, PhD focuses on Lung Cancer and Solid Tumors. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Kai He, MD, PhD currently recruiting for clinical trials?
Yes, Kai He, MD, PhD is currently recruiting for 2 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Kai He, MD, PhD has studied deeply?
Yes, Kai He, MD, PhD has studied treatments such as Pembrolizumab, ONC-392, Docetaxel.
What is the best way to schedule an appointment with Kai He, MD, PhD?
Apply for one of the trials that Kai He, MD, PhD is conducting.
What is the office address of Kai He, MD, PhD?
The office of Kai He, MD, PhD is located at: The Ohio State University James Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the The Ohio State University James Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.